Literature DB >> 11898520

Drug delivery to tumors of the central nervous system.

M S Lesniak1, R Langer, H Brem.   

Abstract

Contemporary treatment of malignant brain tumors has been hampered by problems with drug delivery to the tumor bed. Inherent boundaries of the central nervous system, such as the blood-brain barrier or the blood-cerebrospinal fluid barrier, and a general lack of response to many chemotherapeutic agents have led to alternative treatment modalities. In general, all these modalities have sought to either disrupt or bypass the physiologic brain barriers and deliver the drug directly to the tumor. This article reviews past, as well as current, methods of drug delivery to tumors of the central nervous system. Special emphasis is placed on biodegradable polymers that can release chemotherapeutic agents against malignant gliomas. A variety of other nonchemotherapeutic drugs, including antiangiogenesis and immunotherapeutic agents, are presented in the context of new polymer technology. Finally, future directions in drug delivery are discussed with an overview on new advances in emerging biotechnology.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11898520     DOI: 10.1007/s11910-001-0020-z

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  46 in total

1.  Vector-mediated drug delivery to the brain.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-04-05       Impact factor: 15.470

Review 2.  Targeting drugs to the brain by redox chemical delivery systems.

Authors:  L Prokai; K Prokai-Tatrai; N Bodor
Journal:  Med Res Rev       Date:  2000-09       Impact factor: 12.944

3.  Survival and functional status after resection of recurrent glioblastoma multiforme.

Authors:  F G Barker; S M Chang; P H Gutin; M K Malec; M W McDermott; M D Prados; C B Wilson
Journal:  Neurosurgery       Date:  1998-04       Impact factor: 4.654

4.  Convection-enhanced delivery of macromolecules in the brain.

Authors:  R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

5.  Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors.

Authors:  J Hanes; A Sills; Z Zhao; K W Suh; B Tyler; F DiMeco; D J Brat; M A Choti; K W Leong; D M Pardoll; H Brem
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

6.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

7.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.

Authors:  S B Green; D P Byar; M D Walker; D A Pistenmaa; E Alexander; U Batzdorf; W H Brooks; W E Hunt; J Mealey; G L Odom; P Paoletti; J Ransohoff; J T Robertson; R G Selker; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  Cancer Treat Rep       Date:  1983-02

8.  In vivo versus in vitro degradation of controlled release polymers for intracranial surgical therapy.

Authors:  M P Wu; J A Tamada; H Brem; R Langer
Journal:  J Biomed Mater Res       Date:  1994-03

9.  Cytotoxicity of taxol in vitro against human and rat malignant brain tumors.

Authors:  M A Cahan; K A Walter; O M Colvin; H Brem
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma.

Authors:  K A Walter; M A Cahan; A Gur; B Tyler; J Hilton; O M Colvin; P C Burger; A Domb; H Brem
Journal:  Cancer Res       Date:  1994-04-15       Impact factor: 12.701

View more
  9 in total

1.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

2.  Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells.

Authors:  Cheng Jin; Ling Bai; Hong Wu; Wenjie Song; Guozhen Guo; Kefeng Dou
Journal:  Pharm Res       Date:  2009-04-21       Impact factor: 4.200

3.  Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium.

Authors:  Ramsis K Benjamin; Fred H Hochberg; Elizabeth Fox; Peter M Bungay; William F Elmquist; Clinton F Stewart; James M Gallo; Jerry M Collins; Robert P Pelletier; John F de Groot; Robert C Hickner; Idil Cavus; Stuart A Grossman; O Michael Colvin
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

4.  Gene therapy trials for the treatment of high-grade gliomas.

Authors:  Adam M Sonabend; Ilya V Ulasov; Maciej S Lesniak
Journal:  Gene Ther Mol Biol       Date:  2007

Review 5.  Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier.

Authors:  David S Hersh; Aniket S Wadajkar; Nathan Roberts; Jimena G Perez; Nina P Connolly; Victor Frenkel; Jeffrey A Winkles; Graeme F Woodworth; Anthony J Kim
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

6.  Intranasal Oncolytic Virotherapy with CXCR4-Enhanced Stem Cells Extends Survival in Mouse Model of Glioma.

Authors:  Mahua Dey; Dou Yu; Deepak Kanojia; Gina Li; Madina Sukhanova; Drew A Spencer; Katatzyna C Pituch; Lingjiao Zhang; Yu Han; Atique U Ahmed; Karen S Aboody; Maciej S Lesniak; Irina V Balyasnikova
Journal:  Stem Cell Reports       Date:  2016-09-01       Impact factor: 7.765

7.  Evaluation of adenovirus capsid labeling versus transgene expression.

Authors:  Jing Li; Aiman Fatima; Svetlana Komarova; Hideyo Ugai; Priyanka Uprety; Justin C Roth; Minghui Wang; Robert A Oster; David T Curiel; Qiana L Matthews
Journal:  Virol J       Date:  2010-01-26       Impact factor: 4.099

8.  Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.

Authors:  I V Ulasov; A M Sonabend; S Nandi; A Khramtsov; Y Han; M S Lesniak
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

9.  Cationic PEGylated polycaprolactone nanoparticles carrying post-operation docetaxel for glioma treatment.

Authors:  Cem Varan; Erem Bilensoy
Journal:  Beilstein J Nanotechnol       Date:  2017-07-12       Impact factor: 3.649

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.